Comparator treatments selected for the submission were, therefore, 'no treatment', raloxifene, strontium ranelate, intravenous zoledronic acid, intravenous ibandronate and teriparatide. The main effectiveness evidence for denosumab was derived from a large randomized controlled trial comparing denosumab with placebo. Given by subcutaneous injection at 6-monthly intervals for 3 years, denosumab reduced the incidence of hip fracture by 40%, and reduced the incidence of clinical vertebral fracture by 69%. An indirect treatment comparison was used to derive adjusted relative risk (RR) estimates for different types of fracture for each comparator versus placebo. The RRs (95% CI) applied for denosumab were 0.316 (0.208, 0.478) for clinical vertebral fracture, 0.605 (0.373, 0.983) for hip fracture and 0.842 (0.638, 1.110) for wrist fracture. Despite a number of concerns surrounding the methodology of the indirect comparison, the ERG was satisfied with the robustness of the effect estimates.
The RR estimates were applied in a good-quality Markov model that took account of drug costs, administration and monitoring costs, costs associated with fractures, and long-term nursing home costs. Utility weights were used to adjust time spent in fracture states, allowing QALYs to be estimated. The base-case analysis was conducted for women aged 70 years with a T-score of -2.5 or less and no prior fracture, and women aged 70 years with a T-score of -2.5 or less with a prior fragility fracture. Subgroup analyses based on T-score and independent clinical risk factors were also undertaken.
Applying a willingness-to-pay (WTP) threshold of d30 000 per QALY, the manufacturer's results suggested that denosumab would offer a cost-effective alternative to all treatment comparators for the primary and secondary prevention of fractures. The ERG was concerned about an assumption that denosumab would be administered in general practice at the average cost of two standard GP visits a year. As a result, the ERG requested some further sensitivity analysis and undertook some further modelling, applying an assumption that denosumab would be provided primarily in secondary care. This modification altered the cost effectiveness of denosumab versus 'no treatment' (in women with no prior fragility fracture) and zoledronic acid.
The NICE Appraisal Committee concluded that, as a treatment option for the prevention of osteoporotic fractures, denosumab should be recommended only in post-menopausal women at increased risk of fracture who cannot comply with the special instructions for administering oral bisphosphonates, or have an intolerance of, or contraindication to, those treatments. For primary prevention, the Appraisal Committee also stipulated specific levels of fracture risk at which denosumab is recommended.
Key points for decision makers
Denosumab is an effective treatment for the prevention of osteoporotic fractures in postmenopausal women Cost effectiveness of denosumab is somewhat sensitive to the treatment setting Administered in primary care, denosumab provides a cost-effective treatment option for certain groups of post-menopausal women at increased risk of fracture The National Institute for Health and Clinical Excellence (NICE) is an independent organization whose responsibilities include providing national guidance to the NHS in England and Wales on the use of selected new and established health technologies. One aspect of this is the single technology appraisal (STA) process, which is specifically designed for the appraisal of a single health technology, with a single indication, where most of the relevant evidence lies with one manufacturer or sponsor. [1] Typically, it is used for new pharmaceutical products recently launched. The evidence for an STA is principally derived from a submission by the manufacturer/sponsor of the technology, which should be based on a specification developed by NICE. A report reviewing this evidence submission is then produced by an external organization independent of NICE: the Evidence Review Group (ERG).
The NICE Appraisal Committee then considers the submissions from the manufacturer or sponsor and the ERG, alongside testimony from experts and other stakeholders, to formulate preliminary guidance. All stakeholders have an opportunity to comment on this preliminary guidance, after which the NICE Appraisal Committee meet again to produce the final guidance, known as the Final Appraisal Determination (FAD). This paper presents a summary of the ERG report for the STA of denosumab for the prevention of fragility fractures in post-menopausal women, and the subsequent development of NICE guidance for the use of this drug. This article is one in a series of STA summaries being published in PharmacoEconomics. [2] [3] [4] [5] [6] [7] [8] [9] Full details of all the relevant appraisal documents (including the appraisal scope, ERG report, manufacturer and consultee submissions, Appraisal Consultation Document [ACD], FAD and comments on each of these) can be found on the NICE website.
[10]
The Decision Problem
Post-menopausal osteoporosis has been defined as ''y a progressive, systemic skeletal disorder characterised by low bone mass and micro-architectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture.'' [11] It is estimated that there are 180 000 osteoporosis-related symptomatic fractures each year in England and Wales.
[11] Of these, 70 000 are hip fractures, which require hospital admission and surgical treatment, and are associated with significant morbidity and mortality.
[11] In women aged >50 years, the lifetime risk of a hip fracture is one in five.
[11] After a hip fracture, a high proportion of women are permanently unable to walk independently or to perform other activities of daily living and, consequently, many are unable to live independently. Vertebral fractures can be associated with curvature of the spine and loss of height and can result in pain, breathing difficulties, gastrointestinal problems and difficulties in performing activities of daily living. However, other vertebral fractures may not cause enough discomfort for the woman to seek medical help, and trials distinguish 'clinical fractures' from 'radiographic fractures', the latter detected only by periodic imaging.
The treatment of osteoporosis focuses on altering bone metabolism with the aim of increasing bone mineral density (BMD) and preventing fragility fractures. Bone is in a state of continuous breakdown and renewal. Breakdown is carried out by cells called osteoclasts and renewal by osteoblasts. The cytokine RANK-ligand plays a pivotal role in mediating osteoclast activity. Denosumab is a human monoclonal antibody that inhibits RANK-ligand, thereby reducing osteoclast activity and hence bone breakdown. Marketing authorization for denosumab has been granted by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency. [12] The scope for this appraisal noted that NICE currently recommends alendronate, an oral bisphosphonate, as the first-line treatment for the primary and secondary prevention of fragility fractures, but risedronate, etidronate, raloxifene, strontium ranelate and teriparatide are also recommended for certain groups of women who can not take alendronate. Access to these secondary treatments is dependent on a woman's age, BMD levels and the presence/absence of a number of independent clinical risk factors for fracture. The manufacturer's submission argued that denosumab was clinically and cost effective for the primary and secondary prevention of osteoporotic fractures among post-menopausal women. The submission stated that, because of the availability of inexpensive generic oral bisphosphonates, ''y denosumab is expected to be an appropriate option for diagnosed patients for whom oral [bisphosphonates] are unsuitable; reasons for unsuitability include inability to comply with the special instructions for administration, a contraindication or intolerance.'' [13] Comparator treatments selected for the submission were raloxifene, strontium ranelate, intravenous zoledronic acid, intravenous ibandronate and teriparatide. Since 'no treatment' is recommended for some women who are unable to take oral bisphosphonates under the current NICE guideline, [11] 'no treatment' was also included as a comparator. Due to the method and location of administration, the manufacturer considered intravenous zoledronic acid, intravenous ibandronate and teriparatide to be secondary comparators.
The Independent Evidence Review Group (ERG) Review
The manufacturer (Amgen Inc., UK) provided an evidence submission to NICE on the use of denosumab for the prevention of osteoporotic fracture in post-menopausal women at increased risk of fracture. The submission included a review of evidence relating to the clinical effectiveness of denosumab and its comparators (including an indirect comparison between the alternative drugs), a review of existing cost-effectiveness evidence for denosumab, and a de novo modelling exercise assessing the cost effectiveness of denosumab in relation to a range of comparators.
The University of Aberdeen Health Technology Assessment Group was commissioned as the ERG. The ERG report comprised a critical appraisal of the clinical-effectiveness review, an appraisal of the submitted economic evidence and a critique of the industry model. The ERG re-ran the industry-submitted cost-effectiveness analysis to check results, and assessed the effect of altering some of the key model parameters and assumptions used in the manufacturer's submission. [14] The aims of the ERG review were to (i) assess whether the manufacturer's submission conformed to the methodological guidelines issued by NICE; (ii) assess whether the manufacturer's interpretation and analysis of the evidence were appropriate; and (iii) indicate the presence of other sources of evidence or alternative interpretations of the evidence that could help to inform NICE guidance. The ERG had the opportunity to obtain clarification from the manufacturer on specific uncertainties during the process. This section summarizes the evidence presented in the manufacturer's submission and the ERG's appraisal of that evidence.
Clinical-Effectiveness Evidence
The manufacturer submitted a review of studies assessing the clinical effectiveness of denosumab and its identified comparators. Reviews of the clinical effectiveness of treatment for osteoporosis had been conducted [15] to support the development of a NICE osteoporosis guideline, [16] so the manufacturer updated these by searching for studies published since these reviews.
The main evidence submitted for denosumab was the FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial of denosumab against placebo. [17] The FREEDOM trial was a large good-quality trial involving women with post-menopausal osteoporosis. Denosumab given by subcutaneous injection at 6-monthly intervals for 3 years was effective in reducing fractures. Hip fractures were reduced by 42%, from 1.2% of women in the placebo group to 0.7% in the denosumab group. Clinical vertebral fractures were reduced by 69%, from 2.6% in the placebo group to 0.8% in the denosumab group.
The manufacturer also submitted evidence from studies comparing denosumab with several comparator treatments, with changes in BMD as the primary endpoint. However, given that fracture rates have been reported in trials of denosumab and all comparator treatments, information relating to BMD was not considered by the ERG.
As there were no trials directly comparing denosumab with comparator drugs using fracture rates as the endpoint, the effectiveness of denosumab relative to other bone-loss therapies was estimated from an indirect comparison using trials of other drugs against placebo. The adjusted indirect comparison method described by Bucher et al. [18] was applied. Although not ideal, this is the only approach that could be adopted in the absence of head-to-head trials.
The indirect comparison included a comparison of the relative risks (RRs) of fracture for each drug versus placebo, and an adjusted estimation of the RR of fracture for denosumab versus the other drugs. This demonstrated that denosumab, strontium ranelate and zoledronic acid provided statistically significant decreases in the risk of clinical vertebral fractures (RRs of 0.32, 0.65 and 0.23, respectively) compared with placebo, but that raloxifene did not (RR of 0.45, not significant [NS]). No evidence was identified for the effect of intravenous ibandronate or teriparatide on clinical vertebral fractures compared with placebo. Denosumab and zoledronic acid significantly reduced the risk of hip fractures (RRs of 0.61 and 0.59, respectively) compared with placebo, but strontium ranelate and teriparatide did not (RRs of 0.89 and 0.25, respectively, both NS). Efficacy data on hip fracture were unavailable for the other comparators. None of the treatments produced a significant decrease in the risk of wrist fracture compared with placebo (RR of 0.84 for denosumab, 0.98 for strontium ranelate, 0.29 for teriparatide). No data on wrist fractures were available for the other comparators. The RRs obtained from the direct comparison of each drug with placebo were used to model cost effectiveness. Where no evidence was available for the effect of a comparator on clinical vertebral fractures, a RR for morphometric fracture was applied. Where evidence was unavailable for the effects of comparators on hip and wrist fractures, a RR of 1 was applied. As no evidence was available for the effect of any comparator on other fractures, a RR of 1 was applied for all comparators for this category. Since no efficacy data were identified for intravenous ibandronate, RRs reported for oral ibandronate were applied. [13] 
Critique and Interpretation of the Clinical-Effectiveness Evidence
The ERG was satisfied that the key trials submitted in the clinical evidence review were of good quality, had large numbers of recruits and had adequate follow-up. No further relevant studies were identified in further searches undertaken by the ERG.
Safety data were available from 30 studies, with 14 000 patients, of whom 11 000 were postmenopausal women. Based on these studies, denosumab appears well tolerated. However, a US FDA summary of safety noted that people receiving denosumab appeared to have a slightly increased risk of serious infections of the skin, ear, urinary tract and abdomen. [19] They also noted a non-significant increase in cancer incidence and theoretical concerns about denosumab suppressing dynamic bone formation, leading to delayed fracture healing and atypical fracture. [19] The ERG explored the challenges associated with the adjusted indirect comparison method, and considered whether differences in the baseline characteristics of studies included in the indirect comparison, which could modify the relevant treatment effect, had been taken into account by the manufacturer. On the whole, the methodology appeared sound, but a few potential weaknesses were identified; only one study comparing denosumab with placebo was included, and differences in the quality and baseline characteristics of included studies could have distorted estimates of relative treatment effects. There was a thorough analysis of heterogeneity assumptions in the meta-analysis, but there was a less transparent approach to considering the effects of differences in the baseline characteristics of the studies.
Overall, the ERG were satisfied that the effectiveness of denosumab was not in doubt, and that it appeared well tolerated. The ERG considered that zoledronic acid, which is given by intravenous infusion once a year, should also be considered a key comparator for denosumab.
Cost-Effectiveness Evidence
The manufacturer's submission included a review of existing cost-effectiveness evidence for denosumab, and a de novo cost-effectiveness model comparing denosumab with the identified comparators. The economic analysis focused on the use of denosumab in women at increased risk of fracture (T-score of -2.5 or less) who were unable to take oral bisphosphonates.
Two modelling studies were identified as comparing denosumab with risedronate and 'no treatment', respectively. Strom et al. [20] reported incremental cost per QALY ratios of d10 700 and d14 300 for comparisons with risedronate and 'no treatment', respectively (from a UK healthcare perspective, year 2007 values). Hiligsmann and Reginster [21] found denosumab to be cost effective compared with no treatment (from a Belgian payer perspective). The studies were only available in abstract form, making it difficult to appraise their quality. Further searches undertaken by the ERG identified no further cost-effectiveness studies relevant to the current submission.
The de novo economic evaluation focused on the cost effectiveness of denosumab for (i) the primary prevention of fragility fractures in women with osteoporosis (T-score of -2.5 or less) who are unable to take oral bisphosphonates; and (ii) the secondary prevention of subsequent fragility fractures in women with osteoporosis and prior fragility fractures who are unable to take oral bisphosphonates. A Markov model was used to simulate the transition of cohorts through a series of discrete states, allowing women to experience hip fracture, clinical vertebral fracture, wrist fracture and other types of fracture on a 6-monthly basis. In the base-case analysis, fracture risks were estimated based on epidemiological literature. An alternative risk estimation algorithm (FRAX Ò WHO Fracture Risk Assessment Tool) [22] was applied in a sensitivity analysis to estimate fracture risk in cohorts of women with specific T-scores, with and without additional independent clinical risk factors for fracture.
Costs, and utility multipliers associated with fractures, were derived from a review of the literature. Costs and utility losses associated with wrist fractures and other types of fracture were assumed to last for 1 year, whereas hip fractures and clinical vertebral fractures were modelled to incur ongoing costs and utility losses. A simplifying assumption was made regarding the state transitions allowed in the model: individuals experiencing a vertebral fracture could no longer experience a wrist fracture or other type of fracture (apart from clinical vertebral fractures and hip fractures). After a hip fracture, individuals could no longer experience any type of fracture other than a subsequent hip fracture. This is somewhat unrealistic as experience of a hip or vertebral fracture would put individuals at higher risk of further fractures. It was noted that these assumptions worked in favour of less-efficacious therapies. All-cause mortality was modelled to increase by varying degrees following different types of fracture.
The cost effectiveness of denosumab and its comparators was assessed by superimposing relative treatment effects, derived from the indirect comparison of each treatment option with placebo, and treatment costs on the natural history model. Treatment was assumed to continue for 5 years, and costs and QALYs were tracked over the lifetime of the cohorts. The analysis was conducted from the UK health and social care perspective, costs were valued in d, year 2009 values, and a discount rate of 3.5% per annum was applied to future costs and outcomes. For the base-case analysis, it was assumed that fracture risk would return linearly to baseline levels over the course of 1 year after discontinuation of treatment. Persistence and compliance were also held at 100% for all therapies in the base-case analysis, which would have favoured oral therapies in comparison with denosumab.
The manufacturer's base-case analysis was conducted for cohorts of women aged 70 years with a T-score of -2.5 or less, with and without a prior fragility fracture. It suggested that denosumab would be: more effective and less costly than strontium ranelate in women with and without an existing fracture; cost effective compared with raloxifene, with an incremental cost per QALY of d9289 in women without a previous fracture and~d2000 in those with a previous fracture; borderline cost effective versus no treatment in women without a prior fracture (d29 223 per QALY) and cost effective for women with a prior fragility fracture (d12 381 per QALY); more effective and less costly than intravenous ibandronate in women with and without an existing fracture; less costly and marginally less effective than zoledronic acid, with the incremental cost per QALY for zoledronic acid versus denosumab reported to be d70 900 in women with no previous fracture and d29 029 in those with a previous fracture; less costly and marginally less effective than teriparatide, with the incremental cost per QALY for teriparatide versus denosumab reported to be d772 424 and d451 269 in women with and without a prior fracture, respectively.
Critique and Interpretation of the Cost-Effectiveness Evidence
The ERG deemed the manufacturer's de novo modelling study to be of high quality and in compliance with the NICE reference case. However, a number of concerns were identified, as summarized below.
The manufacturer's base-case analysis considered cost effectiveness in two separate cohorts: (i) women aged 70 years with a T-score of -2.5 or less and no prior fragility fracture; and (ii) women aged 70 years with a T-score of -2.5 or less with a prior fragility fracture. Further subgroup analysis was undertaken for different T-score cut-offs within different age groups. However, it was noted by the ERG that the approach of using fracture risks at or below different T-score thresholds made it difficult to gauge how the cost effectiveness of denosumab varied across T-score bands within age groups; this is the approach that was used to inform previous NICE guidance (TA160, [11] TA161 [23] ). Furthermore, it was noted that the appropriate comparator against which cost effectiveness should be judged would also vary across subgroups of women defined by age and T-score bands. For example, for many women with no prior fragility fracture and a T-score of -2.5 or less, 'no treatment' would be recommended under current NICE guidance.
[11] The ERG, therefore, noted that comparisons between denosumab, raloxifene and strontium needed to be interpreted with caution.
For this reason, the ERG requested some additional subgroup analysis using threshold risks for cohorts with different T-scores. This approach provided a clearer picture of variation in cost effectiveness across age groups and T-score bands. Holding the manufacturer's base-case costing assumptions constant, for primary prevention, the incremental cost-effectiveness ratio (ICER) for denosumab versus no treatment fell below d30 000 per QALY in women aged ‡75 years with a T-score of -2.5 or less, women aged 65-70 years with a T-score of -3 or less, and women aged 55-65 years with a T-score of -4 or less. Denosumab remained cost effective versus no treatment across all subgroups of women with a prior fragility fracture.
The ERG expressed further concern about the assumptions used by the manufacturer to estimate the administration and monitoring costs applied for denosumab in the model. In the basecase analysis, it was assumed that denosumab would be given in primary care, at the cost of two GP visits per year. However, expert advice sought by the ERG cast some doubt over the validity of this assumption. It was suggested that denosumab might be flagged for administration and monitoring in secondary care only. Alternatively, it was suggested that it would at least be initiated in secondary care, and, if GPs did agree to administer it thereafter, they would not do this as part of their general service agreement. It was therefore felt that the average cost of two GP appointments may not adequately capture the marginal cost per patient of administering denosumab. Amgen Inc. had in fact conducted some sensitivity analysis in their original submission to assess the impact of delivering one dose of denosumab per year in secondary care. This change caused the ICER for denosumab versus no treatment to rise above d30 000 per QALY in the cohort aged 70 years with no prior fragility fracture. Given the similar cost and efficacy of denosumab and zoledronic acid, it also resulted in zoledronic acid dominating denosumab for both primary and secondary prevention.
Some additional sensitivity analyses were requested from the manufacturer, to reflect the possibility of denosumab being initiated in secondary care, and GPs demanding enhanced service payments. In addition, the ERG conducted further sensitivity analyses to assess the impact of assuming that denosumab would be delivered entirely in a secondary-care setting. The first of these alterations had limited impact on cost-effectiveness findings, although GP costs were not inflated to account for the possibility of additional payments for denosumab patients. When the cost of denosumab was increased, by assuming it would be delivered entirely in secondary care, the ICER for denosumab compared with no treatment rose to d40 627 per QALY in women aged 70 years with osteoporosis (T-score of -2.5 or less) and no prior fragility fracture, and rose to d17 851 per QALY in women aged 70 years with osteoporosis (T-score of -2.5 or less) and a prior fragility fracture.
The Amgen Inc. submission argued that zoledronic acid and intravenous ibandronate should not be considered primary comparators because they were ''not standard care'' and because they had not been appraised by NICE. However, despite not having been appraised by NICE, both have been licensed for some time and are used in the UK, albeit for a small proportion of patients.
Another potentially inappropriate assumption was used regarding the effect of zoledronic acid on wrist fracture. Due to an absence of direct evidence for the effect of zoledronic acid on wrist fracture, zoledronic acid was assumed to have no effect on this type of fracture in the manufacturer's model, while denosumab was modelled to reduce the risk of wrist fracture by 15.8%. However, according to the manufacturer's indirect comparison, while zoledronic acid and denosumab had similar efficacy for prevention of hip fracture, zoledronic acid had, if anything, slightly higher efficacy for the prevention of non-vertebral fractures; this category included hip fractures, wrist fractures and other types of clinical fracture. Thus, it seemed counter-intuitive to assign denosumab higher efficacy for the prevention of wrist fractures. Therefore, the ERG requested an additional sensitivity analysis assuming equal efficacy of denosumab and zoledronic acid for the prevention of wrist fractures. Holding the manufacturer's base-case costing assumptions constant, this reduced the cost per QALY for zoledronic acid relative to denosumab by about d10 000 for primary prevention and by about d5000 for secondary prevention.
Conclusions of the ERG Report
The manufacturer's submission showed denosumab to be effective in the reduction of fragility fractures in post-menopausal osteoporotic women. The cost effectiveness of denosumab was shown to improve with factors that increased the baseline risk of fracture (compared with less-costly and less-effective alternatives). However, uncertainties remain about the cost of administering the drug.
The comparison with zoledronic acid was sensitive to changes in the relative cost of administering denosumab, and, given the similar efficacy of these two drugs, the ERG found it difficult to separate them on grounds of cost effectiveness.
The ERG also noted that, if denosumab could be delivered within the costs assigned by the manufacturer, then it might be considered cost effective for the primary prevention of fragility fractures in some groups of women for whom 'no treatment' is currently recommended by NICE, i.e. women who cannot take oral bisphosphonates who do not meet the eligibility criteria for strontium ranelate.
Key Methodological Issues
The main methodological issue related to the lack of head-to-head trials comparing the drugs. The main trials of denosumab and zoledronic acid compared them with placebo, not an active comparator. The only way of assessing their relative clinical effectiveness was therefore by an indirect comparison.
Further methodological issues related to the model structure and model validation. The manufacturer opted to use a Markov cohort model utilizing several restrictive assumptions relating to model transitions. By rebuilding the model using micro-simulation techniques, the manufacturer demonstrated that the simplifying assumptions of the Markov cohort model had limited impact on the predicted fracture incidence over the modelled treatment period (5 years).
National Institute for Health and Clinical Excellence Guidance

Preliminary Guidance
After considering the available evidence from the manufacturer and the ERG, the NICE Appraisal Committee were satisfied that denosumab offered an effective treatment for the prevention of fragility fractures. The Committee were also persuaded by expert testimony that denosumab could be delivered predominantly in primary care, but that it would probably be initiated in secondary care, and that some women with severe osteoporosis would also be followed up in secondary care. As a result, the committee were of the opinion that the ICERs for denosumab would be close to those presented in the manufacturer's submission, but would likely be somewhat higher. Therefore, NICE released the following draft guidance in the ACD:
''Denosumab is recommended as a treatment option for the primary prevention of osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures:
who are unable to comply with the special instructions for the administration of oral bisphosphonates, are intolerant of oral bisphosphonates or for whom treatment with oral bisphosphonates is contraindicated and who also have a combination of T-score, 1 age and number of independent clinical risk factors for fracture as indicated in [table I ]. Denosumab is recommended as a treatment option for the secondary prevention of osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures:
who are unable to comply with the special instructions for the administration of oral bisphosphonates, are intolerant of oral bisphosphonates or for whom treatment with oral bisphosphonates is contraindicated. For the purposes of this guidance, independent clinical risk factors for fracture are parental history of hip fracture, alcohol intake of 4 or more units per day, and rheumatoid arthritis.''
[24]
Response to Preliminary Guidance
A variety of responses to the preliminary guidance were raised during the consultation process. The ERG undertook some additional sensitivity analysis, using the manufacturer's model, to address certain concerns raised. Of note, it was suggested that an RR of 0.64 (obtained over 3 years), [25] or an RR of 0.57 (obtained over 5 years), [26] should be used in place of the 0.89 that was used for the effect of strontium ranelate on hip fracture in the submission from Amgen Inc. The ERG considered the RR of 0.89 to be more plausible but, as a sensitivity analysis, applied the RR of 0.64 over the modelled 5-year treatment period in Amgen's model. Denosumab then changed from being dominant over strontium ranelate to costing d10 203 per additional QALY in women aged 70 years with no prior fracture. For women aged 70 years with a prior fracture, the ICER for denosumab versus strontium became d5052 per QALY, i.e. denosumab remained cost effective versus strontium despite this alteration. Applying the RR of 0.57 for the effect of strontium on hip fracture, the ICER for denosumab increased to d16 339 per QALY in women aged 70 years with no prior fracture, and increased to d8639 in women aged 70 years with a prior fracture. Thus, assuming denosumab is administered in primary care, these changes had little impact on conclusions.
The consultation process also drew attention to a price change for zoledronic acid, which was not available in the British National Formulary at the time the ERG undertook their report. An Table I . T-scores (SD) at (or below) which denosumab is recommended when oral bisphosphonates are unsuitable (reproduced from the National Institute for Health and Clinical Excellence, [24] 1 T-score measures BMD using central (hip and/or spine) dual-energy x-ray (DXA) scanning, and is expressed as the number of SDs below peak BMD.
alternative RR estimate of 0.81 for the effect of zoledronic acid on wrist fracture was also suggested. [27] When these two modifications were applied simultaneously, the ICER for zoledronic acid versus denosumab decreased to d44 804 per QALY in osteoporotic women aged 70 years with no prior fragility fracture, and decreased to d18 606 per QALY in osteoporotic women aged 70 years with a prior fragility fracture (assuming Amgen's base-case costing assumptions for denosumab). It should be noted that denosumab and zoledronic acid had similar efficacy.
Final Guidance
Following the responses from consultees and commentators, and consideration of additional analyses undertaken by the ERG, the draft guidance for denosumab remained largely unchanged. However, the term 'oral bisphosphonates' in the draft guidance was replaced more specifically with ''alendronate and either risedronate or etidronate.'' [28] 
Interpretation of the Guidance
The Appraisal Committee were satisfied that denosumab offers an effective treatment for the prevention of fragility fractures in post-menopausal women, and that it can be administered in a primary-care setting. The Appraisal Committee concluded that, as a treatment for the prevention of osteoporotic fractures, denosumab should only be recommended for post-menopausal women at increased risk of fracture ''who are unable to comply with the special instructions for administering alendronate and either risedronate or etidronate, or have an intolerance of, or a contraindication to, those treatments.'' For primary prevention, it was also stipulated that women should have the same level of fracture risk (table I) as described previously in the NICE recommendations for strontium ranelate.
[11] The Committee chose not to recommend denosumab for the primary prevention of fractures in patients who are currently recommended 'no treatment' if they are unable to take oral bisphosphonates, on the grounds that the ICERs for denosumab varied between d19 300 and d71 300 per QALY for these groups. The Committee felt they would, in reality, be somewhat higher given the uncertainties flagged by the ERG. [28] 
